IP Library Granted Patent US 10,307,585
Granted Patent B2
US 10,307,585 · App. 15/898,889 · Granted Jun 4, 2019

Systems and methods to place one or more leads in tissue to electrically stimulate nerves of passage to treat pain

Inventors: Joseph W. Boggs (Chapel Hill, NC); Rosemary H. Zang (Avon Lake, OH)
Assignee: SPR THERAPEUTICS, INC.
A61N1/0551A61N1/0456A61N1/0502A61N1/0558A61N1/36021A61N1/36071A61B5/061A61N1/36017
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,307,585
App. No.
15/898,889
Granted
Jun 4, 2019
Kind
B2
Abstract

Systems and methods are provided for applying electrical stimulation to a body by an electrode spaced from a target nerve of passage. It has been discovered that pain felt, or perceived to be felt, in a given region of the body can be treated by stimulating muscle close to a “nerve of passage” in a region that is superior (i.e., cranial or upstream toward the spinal column) to the region where pain is felt, such as in a case of post-amputation residual limb pain, or purportedly felt in the case of post-amputation phantom limb pain.

Claims (31)

1. A method of reducing a perception of pain, the method comprising the steps of:

placing or instructing placement of an electrode within tissue a distance spaced from (i) at least one of a Type Ia and Ib afferent nerve fibers and (ii) at least one of Type III and Type IV nerve fibers; and

instructing delivery or delivering electrical stimulation through the electrode to selectively activate at least one of the Type Ia and Ib afferent nerve fibers while minimizing recruitment of activation of the at least one of the Type III and Type IV nerve fibers because the electrode is spaced the distance from the at least one of a Type Ia and Ib afferent nerve fibers and the at least one of Type III and Type IV nerve fibers.

2. The method of claim 1 , wherein the electrode is positioned on a lead comprising at least one conductive wire.

3. The method of claim 1 , wherein the delivery of electrical stimulation does not produce a muscle contraction.

4. The method of claim 1 , wherein the delivery of electrical stimulation evokes paresthesia.

5. The method of claim 1 , wherein the tissue comprises muscle tissue.

6. The method of claim 1 , wherein the tissue comprises adipose tissue.

7. The method of claim 1 , wherein the tissue comprises connective tissue.

8. The method of claim 1 , wherein the distance comprises 0.5 to 3 cm.

9. The method of claim 1 , wherein the electrode is positioned on a distal end of a coiled fine wire lead.

10. A method of reducing a perception of pain, the method comprising the steps of:

placing or instructing placement of an electrode in tissue in electrical proximity to but spaced away from a neural fiber bundle within a body, wherein the neural fiber bundle comprises at least one of a Type Ia and Ib afferent nerve fiber and an efferent nerve fiber; and

delivering or instructing delivery of electrical stimulation from the electrode to the neural fiber bundle to reduce a perception of pain, wherein the at least one of Type Ia and Ib afferent nerve fiber of the neural fiber bundle are selectively activated while minimizing recruitment of activation of the efferent nerve fiber of the neural fiber bundle because the electrode is in electrical proximity but spaced away from the neural fiber bundle.

11. The method of claim 10 , wherein selectively activating at least one of the Type Ia and Ib afferent nerve fibers includes selectively activating both of the Type Ia and Ib afferent nerve fibers.

12. The method of claim 11 , wherein minimizing recruitment of activation includes minimizing recruitment of activation of at least one of a Type III and Type IV nerve fiber of the neural fiber bundle.

13. The method of claim 11 , wherein minimizing recruitment of activation includes minimizing recruitment of activation of both the Type III and Type IV nerve fibers of the neural fiber bundle.

14. The method of claim 11 , wherein the tissue comprises muscle tissue.

15. The method of claim 11 , wherein the tissue comprises adipose tissue.

16. The method of claim 11 , wherein the tissue comprises connective tissue.

17. The method of claim 10 , wherein the electrode is a monopolar electrode.

18. The method of claim 10 , wherein the electrical proximity to but spaced away from a neural fiber bundle comprises 0.5 to 3 cm from the neural fiber bundle.

19. the method of claim 10 , wherein the electrode is percutaneously inserted.

20. The method of claim 19 , wherein an introducer needle percutaneously inserts the electrode.

21. A method of reducing a perception of pain, the method comprising the steps of:

placing or instructing placement of an electrode at a therapeutically effective distance from a neural fiber bundle within tissue, wherein the neural fiber bundle comprises more than one type of nerve fiber;

delivering or instructing delivery of electrical stimulation from the electrode to the neural fiber bundle to reduce a perception of pain by said human, wherein a first of the type of nerve fiber is selectively activated while minimizing recruitment of activation of a second of the type of nerve fiber because the electrode is at the therapeutically effective distance; and

evoking or instructing evocation of paresthesia in a region of pain, wherein the region of pain is spaced from the electrode.

22. The method of claim 21 , wherein the therapeutically effective distance is 0.2 centimeters to 3.0 centimeters from the neural fiber bundle.

23. The method of claim 21 , wherein the first type of the type of nerve fiber comprises at least one of Type Ia and Ib afferent nerve fibers and the second of the type of nerve fiber comprises at least one of a Type III, Type IV and efferent nerve fibers.

24. The method of claim 21 , wherein the electrode is placed using an introducer needle percutaneously inserted into the tissue.

Assignments (3)
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 30, 2024
From: SPR THERAPEUTICS, INC.
To: SLR INVESTMENT CORP., AS AGENT
Reel/Frame 066381/0075 →
SECURITY INTEREST Recorded Jan 30, 2024
From: SPR THERAPEUTICS, INC.
To: GEMINO HEALTHCARE FINANCE, LLC
Reel/Frame 066412/0400 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2018
From: BOGGS, JOSEPH W.; ZANG, ROSEMARY H.
To: SPR THERAPEUTICS, INC.
Reel/Frame 045072/0894 →
Continuity (8)
Continuation 13605653 · Sep 6, 2012
Continuation In Part 13294875 · Nov 11, 2011
Continuation In Part 12653023 · Dec 7, 2009
Continuation In Part 12653029 · Dec 7, 2009
Provisional Application 61531462 · Sep 6, 2011
Provisional Application 61412685 · Nov 11, 2010
Provisional Application 61201030 · Dec 5, 2008
Related Publication 20180236222A1 · Aug 23, 2018
Cited By (5)
US 1,084,368 US 12,226,634 US 12,343,537 US 12,420,098 US 12,636,489